PMID- 25424148
OWN - NLM
STAT- MEDLINE
DCOM- 20151217
LR  - 20220318
IS  - 1179-187X (Electronic)
IS  - 1175-3277 (Linking)
VI  - 15
IP  - 1
DP  - 2015 Feb
TI  - Admission hyperglycemia is associated with failed reperfusion following 
      fibrinolytic therapy in patients with STEMI: results of a retrospective study.
PG  - 35-42
LID - 10.1007/s40256-014-0097-9 [doi]
AB  - BACKGROUND: Hyperglycemia on admission is associated with increased mortality 
      rates in patients with ST-elevation myocardial infarction (STEMI) who are treated 
      with either fibrinolytic therapy (FT) or primary percutaneous coronary 
      intervention (PCI). However, data regarding the relationship between 
      hyperglycemia and the success of FT are lacking. The aim of this study was to 
      investigate the value of admission blood glucose for the prediction of failed 
      reperfusion following FT. METHODS AND RESULTS: This is a retrospective study of 
      304 STEMI patients who received FT and whose admission glucose levels were 
      recorded. The main outcome measure was ST segment resolution>/=50%. The median 
      (interquartile range [IQR]) blood glucose level in the entire study group was 112 
      (95-153). In 92 (30.2%) patients, FT was unsuccessful and rescue PCI was 
      performed. Admission glucose (126 [99-192] vs. 110 [94-144] mg/dL, p<0.001), time 
      from symptom onset to FT (180 [120-270] vs. 150 [120-180] min, p=0.009), and 
      maximum ST elevation amplitude (3 [2-7] vs. 3 [2-6] mm, p=0.05) were higher in 
      the failed reperfusion group than in the reperfusion group. Admission 
      hyperglycemia was an independent predictive factor for failed reperfusion (hazard 
      ratio 4.79 [1.80-12.76], p=0.002), along with time from symptom onset to 
      fibrinolysis and anterior wall myocardial infarction. CONCLUSIONS: In patients 
      with STEMI who undergo FT, admission hyperglycemia is an independent predictor of 
      the failure of fibrinolysis.
FAU - Kocas, Cuneyt
AU  - Kocas C
AD  - Department of Cardiology, Istanbul University Institute of Cardiology, Haseki, 
      Aksaray, 34350, Istanbul, Turkey, cuneytkocas@hotmail.com.
FAU - Abaci, Okay
AU  - Abaci O
FAU - Halil, Gulumser Sevgin
AU  - Halil GS
FAU - Arslan, Sukru
AU  - Arslan S
FAU - Cetinkal, Gokhan
AU  - Cetinkal G
FAU - Bostan, Cem
AU  - Bostan C
FAU - Coskun, Ugur
AU  - Coskun U
FAU - Yildiz, Ahmet
AU  - Yildiz A
FAU - Ersanli, Murat
AU  - Ersanli M
LA  - eng
PT  - Journal Article
PL  - New Zealand
TA  - Am J Cardiovasc Drugs
JT  - American journal of cardiovascular drugs : drugs, devices, and other 
      interventions
JID - 100967755
SB  - IM
MH  - Adult
MH  - Angina Pectoris, Variant/etiology/physiopathology/*prevention & control
MH  - Combined Modality Therapy
MH  - Coronary Circulation/*drug effects
MH  - Electrocardiography/drug effects
MH  - Female
MH  - Humans
MH  - Hyperglycemia/epidemiology/*etiology
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/diagnosis/*drug therapy/physiopathology/surgery
MH  - Myocardial Reperfusion Injury/epidemiology/etiology/physiopathology/*prevention & 
      control
MH  - Patient Admission
MH  - Percutaneous Coronary Intervention
MH  - Prevalence
MH  - Prognosis
MH  - Retrospective Studies
MH  - Risk Factors
MH  - *Thrombolytic Therapy
MH  - Time-to-Treatment
MH  - Turkey/epidemiology
EDAT- 2014/11/27 06:00
MHDA- 2015/12/19 06:00
CRDT- 2014/11/27 06:00
PHST- 2014/11/27 06:00 [entrez]
PHST- 2014/11/27 06:00 [pubmed]
PHST- 2015/12/19 06:00 [medline]
AID - 10.1007/s40256-014-0097-9 [doi]
PST - ppublish
SO  - Am J Cardiovasc Drugs. 2015 Feb;15(1):35-42. doi: 10.1007/s40256-014-0097-9.